Pharming (PHAR) Operating Leases (2018 - 2026)

Pharming (PHAR) has 8 years of Operating Leases data on file, last reported at $14.4 million in Q4 2025.

• Quarterly Operating Leases fell 52.03% year-over-year to $14.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.4 million (down 52.03% YoY) and the FY2025 annual result came in at $14.4 million, down 52.03% from the prior year.
• Operating Leases slipped to $14.4 million in Q4 2025, from $29.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $33.3 million in Q4 2022 to a low of $14.4 million in Q4 2025.
• A 5-year average of $26.3 million and a median of $29.9 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases jumped 110.94% — and 2025, when it sank 52.03%.
• Tracing PHAR's Operating Leases over 5 years: stood at $20.9 million in 2021, then jumped by 59.56% to $33.3 million in 2022, then slipped by 0.56% to $33.1 million in 2023, then decreased by 9.69% to $29.9 million in 2024, then slumped by 52.03% to $14.4 million in 2025.
• The last three Operating Leases figures came in at $14.4 million (Q4 2025), $29.9 million (Q4 2024), and $33.1 million (Q4 2023), per Business Quant data.